Initial optimization of a new series of γ-secretase modulators derived from a triterpene glycoside

ACS Medicinal Chemistry Letters

Volumn 3, Issue 11, 2012, Pages 908-913

  Fuller, Nathan O ^a   Hubbs, Jed L ^a   Austin, Wesley F ^a   Creaser, Steffen P ^a,c   McKee, Timothy D ^a   Loureiro, Robyn M B ^a   Tate, Barbara ^a   Xia, Weiming ^a,d   Ives, Jeffrey L ^a   Findeis, Mark A ^a,b   Bronk, Brian S ^a  

^a Satori Pharmaceuticals Incorporated   (United States)

^b Resilientx Therapeutics   (United States)

^c GENZYME CORPORATION   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

secretase; Alzheimer's disease; amyloid ; black cohosh; modulator

Indexed keywords

AGENTS AFFECTING METABOLISM; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CARBOXYLIC ACID; GAMMA SECRETASE; GAMMA SECRETASE MODULATOR; GLYCOSIDE; IMIDAZOLE; MORPHOLINE DERIVATIVE; NOTCH RECEPTOR; PYRIMIDINE DERIVATIVE; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME REGULATION; IN VIVO STUDY; MOUSE; NEUROPROTECTION; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

CIMICIFUGA DAHURICA;

EID: 84868705749     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300256p     Document Type: Article

References (41)

1. Alzheimer's Association. Alzheimer's Disease Facts and Figures. Alzheimer's Dementia 2012, 8 (22), 131-168 (http://www.alz.org/downloads/Facts- Figures-2012.pdf).
2. Wimo, A. P. Alzheimer's Disease International, World Alzheimer's Report 2010: The Global Economic Impact of Dementia, 21 September, 2010.
3. Alzheimer's Disease Medications Fact Sheet, NIH Publication No. 08-3431; Department of Health and Human Services, National Institute on Aging, U.S. Government Printing Office: Washington, D.C., 2010.
4. Cummings, J. L. N. Engl. J. Med. 2004, 351, 56
5. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. Neuropathological Alterations in Alzheimer Disease. In The Biology of Alzheimer Disease; Selkoe, D. J.; Mandelkow, E.; Holtzman, D. M., Eds.; Cold Spring Harbor Perspectives Laboratory Press: Cold Spring Harbor, NY, 2012; pp 43-65.
6. Terry, R. D. Alzheimer's Disease at mid century (1927-1977). In Alzheimer: 100 Years and Beyond; Jucker, M.; Beyreuther, K.; Haass, C.; Nitsch, R., Eds.; Springer-Verlag: Berlin Heidelberg, 2006; pp 58-61.
7. Holtzman, D. M.; Morris, J. C.; Goate, A. M. Alzheimer's disease: The challenge of the second century Sci. Transl. Med. 2011, 3, 77sr1
8. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 2002, 297 (5580) 353-356
9. Haass, C.; Kaether, C.; Thinakaran, G.; Sisodia, S. Trafficking and Proteolytic Processing of APP. In The Biology of Alzheimer Disease; Selkoe, D. J.; Mandelkow, E.; Holtzman, D. M., Eds.; Cold Spring Harbor Perspectives Laboratory Press: Cold Spring Harbor, NY, 2012; pp 205-229.
10. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 2001, 81, 741-766
11. Roher, A. E.; Lowenson, J. D.; Clarke, S.; Woods, A. S.; Cotter, R. J.; Gowing, E.; Ball, M. J. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 10836-10840
12. Iwatsubo, T.; Odaka, A.; Suzuki, N.; Mizusawa, H.; Nukina, N.; Ihara, Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43) Neuron 1994, 13, 45-53
13. Findeis, M. A. The role of amyloid β peptide 42 in Alzheimer's disease Pharmacol. Ther. 2007, 116, 266-286
14. Kreft, A. F.; Martone, R.; Porte, A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease J. Med. Chem. 2009, 52, 6169-6188
15. Panza, F.; Frisardi, V.; Imbimbo, B. P.; Capurso, C.; Logroscino, G.; Sancarlo, D.; Seripa, D.; Vendemiale, G.; Pilotto, A.; Solfrizzi, V. γ-Secretase inhibitors for the treatment of Alzheimer's disease: the current state CNS Neurosci. Ther. 2010, 16 (5) 272-284
16. D'Onofrio, G.; Panza, F.; Frisardi, V.; Solfrizzi, V.; Imbimbo, B. P.; Paroni, G.; Cascavilla, L.; Seripa, D.; Pilotto, A. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease Expert Opin. Drug Discovery 2012, 7, 19-37
17. Lleo, A. Activity of γ-secretase on substrates other than APP Curr. Top. Med. Chem. 2008, 8, 9-16
18. Searfoss, G. H.; Jordan, W. H.; Calligaro, D. O.; Galbreath, E. J.; Schirtzinger, L. M.; Berridge, B. R.; Gao, H.; Higgins, M. A.; May, P. C.; Ryan, T. P. Adipsin, a Biomarker of Gastrointestinal Toxicity Mediated by a Functional γ-Secretase Inhibitor J. Biol. Chem. 2003, 278, 46107-46116
19. Wong, G. T.; Manfra, D.; Poulet, F. M.; Zhang, Q.; Josien, H.; Bara, T.; Engstrom, L.; Pinzon-Ortiz, M.; Fine, J. S.; Lee, H. J.; Zhang, L.; Higgins, G. A.; Parker, E. M. Chronic Treatment with the γ-Secretase Inhibitor LY-411575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation J. Biol. Chem. 2004, 279, 12876-12882
20. Kreft, A. F.; Martone, R.; Porte, A. Recent advances in the identification of γ-secretase inhibitors to clinically test the Aβ oligomer hypothesis of Alzheimer's disease J. Med. Chem. 2009, 52, 6169-6188
21. Hopkins, C. R. ACS Chemical Neuroscience Molecule Spotlight on Semagacestat (LY450139) ACS Chem. Neurosci. 2010, 1, 533-534
22. Oehlrich, D.; Berthelot, D. J.-C.; Gijsen, H. J. M. γ-Secretase Modulators as Potential Disease Modifying Anti-Alzheimer's Drugs J. Med. Chem. 2011, 54, 669-698
23. Wolfe, M. S. γ-Secretase inhibitors and modulators for Alzheimer's disease J. Neurochem. 2012, 120 (1) 89-98
24. Wolfe, M. S. γ-Secretase: Structure, Function, and Modulation for Alzheimer's Disease Curr. Top. Med. Chem. 2008, 8, 2-8
25. Karran, E.; Mercken, M.; De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nat. Rev. Drug Discovery 2011, 10, 698-712
26. Wanngren, J.; Ottervald, J.; Parpal, S.; Portelius, E.; Strömberg, K.; Borgegård, T.; Klintenberg, R.; Juréus, A.; Blomqvist, J.; Blennow, K.; Zetterberg, H.; Lundkvist, J.; Rosqvist, S.; Karlström, H. Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production. J. Biol. Chem. 2012, not supplied.
27. Okochi, M.; Fukumori, A.; Jiang, J.; Itoh, N.; Kimura, R.; Steiner, H.; Haass, C.; Tagami, S.; Takeda, M. Secretion of the Notch-1 Aβ-like Peptide during Notch Signaling J. Biol. Chem. 2006, 281, 7890-7898
28. Weggen, S.; Erikson, J. L.; Das, P.; Sagi, S. A.; Wang, R.; Butler, T.; Kang, D. E.; Marquez-Sterling, N.; Golde, T. E.; Koo, E. H. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity Nature 2001, 414, 212-216
29. Erikson, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, S.; Das, P.; McLendon, D. C.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.; Koo, E. H.; Golde, T. E. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo J. Clin. Invest. 2003, 112, 440-449
30. Galasko, D. R.; Graff-Radford, N.; May, S.; Hendrix, S.; Cottrell, B. A.; Sagi, S. A.; Mather, G.; Laughlin, M.; Zavitz, K. H.; Swabb, E.; Golde, T. E.; Murphy, M. P.; Koo, E. H. Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals Alzheimer's Dis. Assoc. Disord. 2007, 21, 292-299
31. Green, R. C.; Schneider, L. S.; Amato, D. A.; Beelen, A. P.; Wilcock, G.; Swabb, E. A.; Zavitz, K. H.; Tarenflurbil Phase 3 Study Group Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial J. Am. Med. Assoc. 2009, 302, 2557-2564
32. Borgegard, T.; Jeréus, A.; Olsson, F.; Rosqvist, S.; Sabirsh, A.; Rotticci, D.; Paulsen, K.; Klintenberg, R.; Yan, H.; Waldman, M.; Stromberg, K.; Nord, J.; Johansson, J.; Regner, A.; Parpal, S.; Malinowsky, D.; Radesater, A.-C.; Li, T.; Singh, R.; Eriksson, H.; Lundkvist, J. First and Second Generation γ-Secretase Modulators (GSMs) Modulate Amyloid-β (Aβ) Peptide Production through Different Mechanisms J. Biol. Chem. 2012, 287, 11810-11819
33. Findeis, M. A.; Schroeder, F.; McKee, T. D.; Yager, D.; Fraering, P. C.; Creaser, S. P.; Austin, W. F.; Clardy, J.; Wang, R.; Selkoe, D. J.; Eckman, C. B. Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa. ACS Chem. Neurosci. DOI: 10.1021/cn3000857; manuscript in press.
34. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties ACS Chem. Neurosi. 2010, 1, 435-449
35. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes ACS Chem. Neurosci. 2010, 1, 420-434
36. Lipinski, C. A.; Lombardo, R.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
37. Austin, W. F.; Hubbs, J. L.; Fuller, N. O.; Creaser, S. P.; McKee, T. D.; Loureiro, R. M. B.; Findeis, M. A.; Tate, B.; Ives, J. L.; Bronk, B. S. SAR investigations on a novel class of gamma-secretase modulators based on a unique scaffold. (Manuscript submitted for publication).
38. Du, M.; Hindsgaul, O. Novel Hybrid Morpholino-Glycopeptides with the Amino Acid Nitrogen Replacing C-3 of the Pyranose Ring Synlett 1997, 395-397
39. Chan, J. Y. C.; Hough, L.; Richardson, A. C. J. The Synthesis of (R)- and (S)-Spirobi-1,4-dioxane and Related Spirobicycles from D-Fructose J. Chem. Soc., Perkin. Trans. 1 1985, 7, 1457-1462
40. a, ClogP, and tPSA predictions in this paper were calculated using algorithms included in MarvinSketch, version 5.4.1.1; ChemAxon: Budapest, Hungary, 2011.
41. 50 for Merck GSM-1 = >350, for JNJ-40418677 = >20, for Eisai E-2012 = >400). See "An improved cell-based method for determining the gamma-secretase enzyme activity against both NOTCH and APP substrates", T. D. McKee, et al., AAIC 2012, poster #P2-095, http://www.satoripharma.com/news-events/publications-and-presentations. php.